Article Text

Download PDFPDF
Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)
  1. A E Rodríguez1,
  2. M Rodríguez Alemparte1,
  3. C F Vigo1,
  4. C Fernández Pereira1,
  5. C Llauradó1,
  6. D Vetcher2,
  7. A Pocovi2,
  8. J Ambrose3
  1. 1Cardiac Unit, Otamendi Hospital, Buenos Aires School of Medicine, Buenos Aires, Argentina
  2. 2Argentina Society for Cardiac Interventions (CACI), Buenos Aires, Argentina
  3. 3Cardiac Unit, Saint Vincent Hospital, New York, New York, USA
  1. Correspondence to:
    Dr Alfredo E Rodriguez
    Cardiac Unit, Otamendi Hospital, Azcuénaga 870, Buenos Aires, Argentina C1115 AAB;


Objective: To assess the role of oral rapamycin in the prevention of coronary restenosis in patients undergoing coronary stenting.

Methods: From December 2001 through February 2003, 76 patients with 103 de novo lesions treated percutaneously with bare stents received a loading dose of oral rapamycin 6 mg followed by a daily dose of 2 mg during 28 days in phase I (49 arteries in 34 patients) and 2 mg/day plus 180 mg/day of diltiazem in phase II (54 arteries in 42 patients). Rapamycin blood concentrations were measured in all patients. A six month follow up angiogram was performed in 82.5% (85 of 103 arteries). Follow up angiographic binary restenosis (> 50%), target vessel revascularisation, late loss, treatment compliance, and major adverse cardiovascular events were analysed and correlated with rapamycin concentrations.

Results: Rapamycin was well tolerated and only three patients discontinued the treatment for mild side effects. Angiographic restenosis was found in 15% of the arteries with angiographic restudy (13 of 85). The target vessel had been revascularised at follow up in 13.6% of the 103 vessels initially treated (14 of 103) and in 18.4% of the 76 patients (14 of 76). In-stent restenosis in phase I was 19% compared with 6.2% in phase II (p  =  0.06). Angiographic in-stent restenosis in lesions of patients with rapamycin blood concentrations ⩾ 8 ng/ml was 6.2% and with rapamycin concentrations < 8 ng/ml was 22% (p  =  0.041). Late loss was also significantly lower when rapamycin concentrations were ⩾ 8 ng/ml (0.6 mm v 1.1 mm, p  =  0.031). A Pearson test showed a linear correlation between follow up late loss and rapamycin blood concentration (r  =  −0.826, p  =  0.008).

Conclusion: Oral rapamycin administered for one month after percutaneous coronary intervention was safe and with few minor side effects. High rapamycin blood concentrations were associated with significantly lower late loss and angiographic in-stent restenosis.

  • CACI, Argentina Society for Cardiac Interventions
  • MACE, major adverse cardiovascular events
  • MLD, minimum luminal diameter
  • PCI, percutaneous coronary intervention
  • ORBIT, oral Rapamune to inhibit restenosis
  • coronary stents
  • restenosis
  • rapamycin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • No authors have any financial associations that may pose a conflict of interest in connection with this manuscript.